“Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B”, Clinics, vol. 68, no. 10, pp. 1325–1332, Oct. 2013, doi: 10.1590/clin.v68i10.77009.